Loading published resources...
Tumor-immunology domain studying how host genetic background shapes response to cancer immunotherapy in diverse mouse F1 panels; published work used DO×B6 F1 for the main screen and CC×B6 F1 for validation of genetically controlled checkpoint-inhibitor responses in syngeneic tumor models.
Basic research on immune responses and inflammatory regulation, featuring a non-live-pathogen inflammatory reference model.
Domain entry for immune-mediated inflammation and idiosyncratic drug toxicity, covering two literature directions: CC spontaneous-colitis line CC011/Unc as an intestinal inflammation reference, and the CC multi-strain panel for tolvaptan idiosyncratic liver-injury susceptibility.
Research on axon growth and repair after central nervous system injury. Published comparisons of the CAST/Ei and C57BL/6 inbred strains provide a reference for genetic-background effects on CNS regeneration.
Variability of response and primary resistance to cancer immune checkpoint inhibition, studied in genetically diverse mouse F1 populations.
Spontaneous solid-tumor susceptibility in a genetically diverse mouse population: published surveillance across multiple Collaborative Cross (CC) strains showed broad variation in spontaneous tumor incidence and spectrum, and identified CC036 as a spontaneous gastric-tumour model.
Domain entry for idiosyncratic drug-induced liver injury (DILI): published work used the CC multi-strain panel (45 strains) to study tolvaptan-induced liver injury susceptibility and biomarkers; ADPKD is only the clinical context of the drug, and no kidney-injury model evidence is cited for this entry.
Core reporting items, planned versus performed research, and official sources.